Latikort

Latikort – local drug with glucocorticoid, antiinflammatory, antipruritic, anti-exudative, antiallergic action.

Form of release and structure

Latikort release in three dosage forms for external use:

• Cream of 0,1%: white homogeneous mass (on 15 g in aluminum tubas, on 1 tuba in a cardboard pack);
• Ointment of 0,1%: almost colourless, transparent fat weight (on 15 g in aluminum tubas, on 1 tuba in a cardboard pack);
• Solution of 0,1%: transparent, colourless, without mechanical inclusions and a deposit, has a smell of isopropyl alcohol (on 20 ml in polyethylene bottles, on 1 bottle in a cardboard pack).

Is a part of 1000 mg of cream:

• Active ingredient: hydrocortisone butyrate – 1 mg;
• Auxiliary components: liquid paraffin – 60 mg, white vaseline – 150 mg, цетомакрогол – 18 mg, cetostearyl alcohol – 72 mg, methylparahydroxybenzoate – 2 mg, citric acid – 4,2 mg, sodium citrate – 2,8 mg, the purified water – to 1000 mg.

Is a part of 1000 mg of ointment:

• Active ingredient: hydrocortisone butyrate – 1 mg;
• Auxiliary components: white vaseline – to 1000 mg.

Is a part of 1 ml of solution:

• Active ingredient: hydrocortisone butyrate – 1 mg;
• Auxiliary components: povidone – 2,5 mg, глицерол – 30 mg, citric acid – 1,72 mg, isopropanol – 0,5 mg, sodium citrate – 0,78 mg, the purified water – to 1 ml.

Indications to use

Latikort appoint for treatment of the local glucocorticosteroids which are not infected, showing sensitivity to action, skin diseases which proceed with excessive keratinization:

• Seborrheal and atopic dermatitis;
• Red flat deprive;
• Erythrosis;
• Psoriasis;
• Contact eczema.

Also drug is appointed at stings of insects.

Contraindications

• Infections of skin of a bacterial, virus and fungal etiology;
• Syphilitic or tubercular damages of skin;
• Perioral dermatitis;
• Pink eels, acne vulgaris;
• Skin tumors;
• Disturbances of integrity of integuments (wound, ulcer);
• Postvaccinal period;
• Age up to 6 months, at an itch in the field of an anus – up to 12 years;
• Hypersensitivity to drug components.

Latikort appoint with care the patient with a diabetes mellitus and tuberculosis (at systemic lesion).

Pregnant women can use drug only on doctor's orders after assessment of a ratio of potential advantage with possible risk. Latikort it is possible to apply on small areas of skin with a short course. In the I trimester of pregnancy use of drug is not recommended.

In the period of a lactation it is possible to carry out short-term therapy with putting drug on small sites of skin. On skin of a mammary gland it is not necessary to apply Latikort.

Route of administration and dosage

Latikort apply outwardly.

The recommended dosing mode at adults – 1-3 times a day. Drug in a small amount should be applied with the massing movements on affected areas of skin. Course duration – 1-3 weeks. Within a week the total dose of drug should not exceed 30-60 g. At resistant disease, for example, at the dense psoriasis plaques localized on a lap and elbows, Latikort it is necessary to apply under occlusive bandages.

To children drug is appointed from six-months age. Because of more bystry development of suppression of function of bark of adrenal glands and probability of decrease in excretion of a growth hormone at Latikort's use for children by a long course it is necessary to watch growth, body weight, plasma cortisol level.

When putting drug on the person or under occlusive bandages (diapers, pampers) absorption happens more therefore use of the minimum doses of drug is recommended. Therapy has to be carried out shortly and under medical control.

Side effects

Side effects are observed seldom. Latikort's uses developing in time disturbances usually have reversible character.

In rare instances there can be local reactions which are shown in the form of irritation of skin and also allergic contact dermatitis.

At long therapy and/or Latikort's drawing on extensive areas, when using occlusive bandages such disturbances as in some cases can develop: folliculitis, aknepodobny changes, heat rash, hypopigmentation, striya, consecutive infections of skin, hypertrichosis, skin atrophy.

Special instructions

It is necessary to avoid Latikort's hit in eyes.

At development of consecutive infection of a fungal or bacterial etiology it is necessary to use outside antibacterial or antifungal drugs.

Extra care is demanded by Latikort's use on face skin that is connected with probability of development of side effects (an atrophy, teleangiectasias, perioral dermatitis).

In cases if after 7 days of therapy the state does not improve, or, on the contrary, worsens, and also when resuming symptoms in several days after drug withdrawal, it is necessary to stop Latikort's use and to consult with the specialist.

In spite of the fact that long use of high doses of drug, in particular when using occlusive bandages, can lead to increase in maintenance of cortisol in a blood plasma, it is never followed by decrease in reactivity of pituitary and adrenal system. After therapy cancellation products of cortisol are quickly normalized.

The probability of development of side effects during Latikort's use is lower, than at therapy by the halogenated glucocorticosteroids.

It is necessary to be careful when using drug at patients with atrophic conditions of skin, in particular at patients of advanced age.

Latikort in the form of ointment it is recommended to apply at lichenification and subacute inflammatory states.

Medicinal interaction

Data on Latikort's interaction with other drugs are not submitted.

Terms and storage conditions

To store in the place, unavailable to children, at a temperature up to 25 °C.

Period of validity – 3 years.